Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
40%(2 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
1
20%
Ph phase_4
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).

NCT04657744
completed

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya

NCT02137707
completed

Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.

NCT02225977
completedphase_2

Gilenya in Amyotrophic Lateral Sclerosis (ALS)

NCT01786174
completedphase_4

Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS

NCT02048072

Clinical Trials (5)

Showing 5 of 5 trials
NCT04657744Phase 1

Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).

Completed
NCT02137707

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya

Completed
NCT02225977

Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.

Completed
NCT01786174Phase 2

Gilenya in Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT02048072Phase 4

Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5